While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. That said, here are three cash-producing companies to steer clear of and a few better alternatives.
8x8 (EGHT)
Trailing 12-Month Free Cash Flow Margin: 5.5%
Named after its founding year (1987) with "8x8" representing binary code for communications, 8x8 (NASDAQ: EGHT) provides cloud-based contact center and unified communications solutions that enable businesses to manage customer interactions and internal communications through a single platform.
Why Do We Steer Clear of EGHT?
- Customers had second thoughts about committing to its platform over the last year as its average billings growth of 2.4% underwhelmed
- Sales are projected to be flat over the next 12 months and imply weak demand
- Operating margin increased by 2.1 percentage points over the last year as it refined its cost structure
8x8 is trading at $1.94 per share, or 0.4x forward price-to-sales. Check out our free in-depth research report to learn more about why EGHT doesn’t pass our bar.
Standex (SXI)
Trailing 12-Month Free Cash Flow Margin: 5.9%
Holding over 500 patents globally, Standex (NYSE: SXI) is a manufacturer and distributor of industrial components for various sectors.
Why Does SXI Worry Us?
- Estimated sales growth of 6.9% for the next 12 months implies demand will slow from its two-year trend
- Free cash flow margin dropped by 3.2 percentage points over the last five years, implying the company became more capital intensive as competition picked up
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $254.21 per share, Standex trades at 27.6x forward P/E. If you’re considering SXI for your portfolio, see our FREE research report to learn more.
Bruker (BRKR)
Trailing 12-Month Free Cash Flow Margin: 1.3%
With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ: BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.
Why Does BRKR Fall Short?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 6.8 percentage points
- Waning returns on capital imply its previous profit engines are losing steam
Bruker’s stock price of $34.09 implies a valuation ratio of 15.9x forward P/E. Read our free research report to see why you should think twice about including BRKR in your portfolio.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
